The European Commission’s “ Choose Europe for Life Sciences” strategy , launched to make the European Union the global hub for biotechnology, healthcare, food systems, and green manufacturing by 2030, is an audacious bid to reshape the life sciences landscape. With a promise to streamline regulation, mobilise investment, and foster collaborative research and innovation (R&I), the blueprint beckons global partners to a revitalised European ecosystem. For India, the world’s pharmacy, and Telangana, its life sciences powerhouse, the strategy offers a chance to deepen ties with a $1.5 trillion market, drive economic growth, and cement their roles in global innovation. Yet, seizing this moment requires bold, coordinated action from policymakers. Here’s how India and Telangana can capitalise—and what they must do to stay ahead. India’s Strategic Play India, with a $50 billion pharmaceutical industry and a 60% share of global vaccine production, is well-placed to align with the EU’s ambit...